Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  quizartinib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 60
Sponsor: Other
Protocol IDs: SPON 845-10, 2010-021444-18, 10/MRE09/27, NCT01236144
Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: AC220-002, NCT00989261
Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2689-CL-2004, 2011-005408-13, NCT01565668
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP0001, NCT00462761
Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AC220-004, NCT01049893
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2689-CL-0005, NCT01390337
A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 1 to 21
Sponsor: Other
Protocol IDs: T2009-004, NCT01411267
A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2689-CL-0011, NCT01468467
Start Over